Comparison of the efficacy of Rifaximin with Mebeverine on gastrointestinal symptoms in patients with irritable bowel syndrome

Comparison of the efficacy of Rifaximin versus Mebeverine on gastrointestinal symptoms in patients with irritable bowel syndrome.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210115050039N1

Enrollment

100

Registered

2025-10-07

Start date

2018-05-14

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome. Irritable bowel syndrome [K58]: A functional bowel disorder characterized by abdominal pain or discomfort that is associated with defecation or a change in bowel habits

Interventions

Intervention 1: Intervention group: Patients receiving rifaximin (rifaximin 200 mg every 8 hours for 10 days). Intervention 2: Control group: Receiving Mebeverine (200 mg one morning and one evening,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of different ages Patients with IBS Patient consent to participate in the study Do not take interfering drugs Lack of sensitivity to Mebeverine Lack of sensitivity to rifaximin

Exclusion criteria

Exclusion criteria: - Patients' dissatisfaction - Sensitivity to Mebeverine - Sensitivity to rifaximin - Receiving interfering drugs

Design outcomes

Primary

Measure	Time frame
Daily stress levels. Timepoint: Before the intervention and 4 weeks after the end of the intervention. Method of measurement: Interview Using the standard Perceived Stress Scale (PSS-10) questionnaire.;Changes in gastrointestinal symptom severity (abdominal pain, bloating, and altered bowel habits) after the intervention. Timepoint: Before the intervention and 4 weeks after the end of the intervention. Method of measurement: Using the standardized IBS Symptom Severity Scale questionnaire.	—

Measure

Time frame

Daily stress levels. Timepoint: Before the intervention and 4 weeks after the end of the intervention. Method of measurement: Interview Using the standard Perceived Stress Scale (PSS-10) questionnaire.;Changes in gastrointestinal symptom severity (abdominal pain, bloating, and altered bowel habits) after the intervention. Timepoint: Before the intervention and 4 weeks after the end of the intervention. Method of measurement: Using the standardized IBS Symptom Severity Scale questionnaire.

—

Secondary

Measure	Time frame
The pain. Timepoint: Before the intervention and 4 weeks after the end of the intervention. Method of measurement: Interview Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain).;Blowing. Timepoint: Before the start of the intervention, 2 weeks after the end of the intervention, and 4 weeks after the end of the intervention. Method of measurement: Interview The bloating subscale of the standardized IBS Symptom Severity Scale-S (IBS-SSS) was self-administered by the patient.	—

Measure

Time frame

The pain. Timepoint: Before the intervention and 4 weeks after the end of the intervention. Method of measurement: Interview Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain).;Blowing. Timepoint: Before the start of the intervention, 2 weeks after the end of the intervention, and 4 weeks after the end of the intervention. Method of measurement: Interview The bloating subscale of the standardized IBS Symptom Severity Scale-S (IBS-SSS) was self-administered by the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Alinejad Khorram

Islamic Azad University

alinejadkhoram@gmail.com+98 21 2629 5276

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026